Betoptic eye drops 0.5%, 5 ml

• Intraocular hypertension;

• open-angle glaucoma.

It can be used in the treatment of patients with open-angle glaucoma and intraocular hypertension in combination with respiratory pathology.

Into the conjunctival sac. 1-2 drops, 2 times a day.

In some patients, IOP stabilization occurs within a few weeks, so it is recommended to monitor it during the first month of treatment.

If the required IOP level is not achieved with Betoptic monotherapy, additional therapy should be prescribed.

Eye drops 0.5% in the form of a transparent colorless or slightly yellowish solution.

1 ml

betaxolol hydrochloride 5.6 mg,

which corresponds to the content of betaxolol 5 mg

Excipients: benzalkonium chloride, hydrochloric acid and / or sodium hydroxide solution (to maintain the pH level), purified water.

• Individual hypersensitivity to the components of the drug.

With care: sinus bradycardia, AV block II Ц III degree, cardiogenic shock, severe heart failure, myasthenia gravis, diabetes mellitus.

pharmachologic effect

Antiglaucoma drug. Selective beta1-blocker without intrinsic sympathomimetic activity. Does not have a membrane stabilizing (local anesthetic) effect.

When applied topically, betaxolol reduces intraocular pressure by reducing the production of intraocular fluid.

The onset of hypotensive action is observed 30 minutes after instillation, the maximum effect develops after 2 hours. After a single instillation, the effect on ophthalmotonus lasts for 12 hours.

Betaxolol (in comparison with other beta-blockers) does not cause a decrease in blood flow in the optic nerve.

The use of Betoptic does not lead to the occurrence of miosis, accommodation spasm, hemeralopia, the effect of a 'veil' before the eyes (unlike miotics).

Pharmacokinetics

With local application of the drug, systemic absorption of betaxolol hydrochloride is possible.

Side effect

From the side of the organ of vision: often - short-term discomfort in the eyes after instillation, lacrimation; in some cases - decreased sensitivity of the cornea, redness of the eye, punctate keratitis, photophobia, anisocoria, photophobia, itching, dry eyes.

From the side of the central nervous system: rarely - insomnia, depressive neuroses.

Application during pregnancy and lactation

There is no sufficient experience of using the drug Betoptic during pregnancy and lactation. The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the intended benefit to the mother outweighs the potential risk to the fetus or child.

Application in children

There is no sufficient experience of using the drug Betoptic in children.

special instructions

The drug is prescribed with caution to patients with diabetes mellitus, since beta-blockers can mask the symptoms of acute hypoglycemia.

The drug is prescribed with caution to patients with thyrotoxicosis, because beta-blockers can mask the symptoms of thyrotoxicosis (eg, tachycardia). In patients with suspected thyrotoxicosis, beta-blockers should not be abruptly canceled, because this can lead to increased symptoms.

It should be borne in mind that beta-blockers can cause symptoms similar to those in myasthenia gravis (diplopia, ptosis, general weakness).

Precautions should be taken in prescribing beta-blockers to patients with severe impairment of the respiratory system. Despite the fact that clinical studies have shown the absence of the effect of betaxolol on the function of external respiration, the possibility of increased sensitivity to the drug cannot be ruled out.

Before a planned surgery, beta-blockers should be gradually withdrawn 48 hours before general anesthesia. during general anesthesia, they can reduce the sensitivity of the myocardium to sympathetic stimulation.

Patients using beta-blockers may have a history of atopy or anaphylactic reactions. If repeated hypersensitivity reactions develop, such patients may not be sensitive to the usual doses of epinephrine (adrenaline) required to stop anaphylaxis.

The drug should be used with caution in patients with Raynaud's syndrome or pheochromocytoma.

When instilled into the eyes, beta-blockers can be absorbed into the systemic circulation. In this case, the same side effects may be noted as with systemic use. Cases of severe respiratory and cardiovascular disorders have been described, including fatal bronchospasm in patients with bronchial asthma and death from heart failure.

Betoptic has a minimal effect on blood pressure and heart rate. However, caution should be exercised when prescribing the drug to patients with AV block or heart failure. Treatment with Betoptic should be stopped immediately when the first symptoms of decompensation from the cardiovascular system appear.

Care should be taken when using Betoptic and adrenergic psychotropic drugs together.

Betoptic eye drops contain preservatives that can be deposited in soft contact lenses and have a damaging effect on the tissues of the eye. Therefore, patients wearing contact lenses should remove them before applying drops and reinstall them no earlier than 20 minutes after instillation.

Use in pediatrics

There is no sufficient experience of using the drug Betoptic in children.

Influence on the ability to drive vehicles and mechanisms

If, after using the drops, the clarity of vision temporarily decreases in patients, it is not recommended to drive a car and engage in activities that require increased attention and reaction until it is restored.

Overdose

In case of contact with the eyes of an excessive amount of the drug, rinse the eyes with warm water.

Drug interactions

With the simultaneous use of the drug Betoptic and beta-blockers for oral administration, the risk of side effects (both local and systemic) increases due to the additive effect (therefore, patients receiving this combination of drugs should be under medical supervision).

When Betoptic is used in combination with drugs that deplete catecholamines (such as reserpine), a decrease in blood pressure and bradycardia can be observed.